At day 22, the seroprotection rates ranged between 96% and 99% for all four vaccine strains in the QIVc and TIV1c/TIV2c groups. test vaccine, Vaxiflu-4, showed non-inferiority in terms of immunogenicity and security when compared with research vaccine, Fluarix Tetra (Clinical trial registry number: CTRI/2022/05/042514). KEYWORDS:Influenza, pediatric vaccination, security profile, tetravalent inactivated vaccine, Immunogenicity == […]